Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Jump to content

Quazinone

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Quazinone
Clinical data
Other namesRo 13-6438
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • (3R)-6-Chloro-3-methyl-5,10-dihydroimidazo[2,1-b]quinazolin-2(3H)-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H10ClN3O
Molar mass235.67 g·mol−1
3D model (JSmol)
  • Clc1cccc3c1CN2/C(=N\C(=O)[C@H]2C)N3

Quazinone (Dozonone) is a cardiotonic and vasodilator drug which was developed and marketed in the 1980s for the treatment of heart disease.[1][2][3][4][5] It acts as a selective PDE3 inhibitor.[6][7] It is no longer available.[1]

See also

References

  1. ^ a b David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 978-0-412-46630-4.
  2. ^ Eigenmann R, Gerold M, Holck M (1984). "Cardiovascular profile of Ro 13-6438, a novel positive inotropic agent with vasodilating properties". Journal of Cardiovascular Pharmacology. 6 (3): 511–9. doi:10.1097/00005344-198405000-00021. PMID 6202980. S2CID 35907876.
  3. ^ Holck M, Thorens S, Muggli R, Eigenmann R (1984). "Studies on the mechanism of positive inotropic activity of Ro 13-6438, a structurally novel cardiotonic agent with vasodilating properties". Journal of Cardiovascular Pharmacology. 6 (3): 520–30. doi:10.1097/00005344-198405000-00022. PMID 6202981. S2CID 13286049.
  4. ^ Belz GG, Stern HC, Butzer R (1985). "Dose-response following single administrations of a new cardiac performance enhancer RO 13-6438 in normal volunteers". Journal of Cardiovascular Pharmacology. 7 (1): 86–90. doi:10.1097/00005344-198501000-00014. PMID 2580156. S2CID 27819870.
  5. ^ Daly PA, Chatterjee K, Viquerat CE, et al. (June 1985). "RO13-6438, a new inotrope-vasodilator: systemic and coronary hemodynamic effects in congestive heart failure". The American Journal of Cardiology. 55 (13 Pt 1): 1539–44. doi:10.1016/0002-9149(85)90969-5. PMID 4003296.
  6. ^ Osinski MT, Schrör K (August 2000). "Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis". Biochemical Pharmacology. 60 (3): 381–7. doi:10.1016/S0006-2952(00)00328-2. PMID 10856433.
  7. ^ Denis D, Riendeau D (February 1999). "Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes". European Journal of Pharmacology. 367 (2–3): 343–50. doi:10.1016/S0014-2999(98)00987-X. PMID 10079010.
  • Media related to Quazinone at Wikimedia Commons